Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types

References

• RosenbergSAYangJCTopalianSLTreatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2JAMA1994271129079138120958
   PubMed Web of Science ®Google Scholar
• KirkwoodJMStrawdermanMHErnstoffMSSmithTJBordenECBlumRHInterferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684J Clin Oncol19961417178558223
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• KantoffPWHiganoCSShoreNDSipuleucel-T immunotherapy for castration-resistant prostate cancerN Engl J Med2010363541142220818862
   PubMed Web of Science ®Google Scholar
• ZajacAJBlattmanJNMurali-KrishnaKViral immune evasion due to persistence of activated T cells without effector functionJ Exp Med199818812220522139858507
   PubMed Web of Science ®Google Scholar
• WherryEJT cell exhaustionNat Immunol201112649249921739672
   PubMed Web of Science ®Google Scholar
• VirginHWWherryEJAhmedRRedefining chronic viral infectionCell20091381305019596234
   PubMed Web of Science ®Google Scholar
• BarberDLWherryEJMasopustDRestoring function in exhausted CD8 T cells during chronic viral infectionNature2006439707768268716382236
   PubMed Web of Science ®Google Scholar
• TrautmannLJanbazianLChomontNUpregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunctionNat Med200612101198120216917489
   PubMed Web of Science ®Google Scholar
• FranciscoLMSalinasVHBrownKEPD-L1 regulates the development, maintenance, and function of induced regulatory T cellsJ Exp Med2009206133015302920008522
   PubMed Web of Science ®Google Scholar
• DayCLKaufmannDEKiepielaPPD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progressionNature2006443710935035416921384
   PubMed Web of Science ®Google Scholar
• PetrovasCCasazzaJPBrenchleyJMPD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infectionJ Exp Med2006203102281229216954372
   PubMed Web of Science ®Google Scholar
• ParryRVChemnitzJMFrauwirthKACTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanismsMol Cell Biol200525219543955316227604
   PubMed Web of Science ®Google Scholar
• KEYTRUDA^® (pembrolizumab) [package insert]Whitehouse Station, NJMerck2014Accessed November 26, 2014
   Google Scholar
• HamidOEfficacy and safety of MK-3475 in patients with advanced melanomaPresented at: The Society for Melanoma Research 2012 CongressHollywood, CANovember 8–11, 2012
   Google Scholar
• HamidORobertCDaudASafety and tumor responses with lambrolizumab (anti-PD-1) in melanomaN Engl J Med2013369213414423724846
   PubMed Web of Science ®Google Scholar
• RobertCRibasAWolchokJDAnti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialLancet201438499481109111725034862
   PubMed Web of Science ®Google Scholar
• HamidORobertCRibasARandomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL) [abstr 3000]J Clin Oncol201432Suppl5S
   Google Scholar
• RibasAHodiFSKeffordREfficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL) [abstr LBA9000]J Clin Oncol201432Suppl5S
   Google Scholar
• JosephRWElassaiss-SchaapJWolchokJBaseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475 [abstr 3015]J Clin Oncol201432Suppl5S
   Google Scholar
• WolchokJDHoosAO’DaySGuidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaClin Cancer Res200915237412742019934295
   PubMed Web of Science ®Google Scholar
• HodiFSRibasADaudAEvaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475 [abstr 3006]J Clin Oncol201432Suppl5S
   Google Scholar
• RibasAPuzanovIDummerRA randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanomaPresented at: Society for Melanoma Research 2014 International CongressZurich, Switzerland13–16 November, 2014
   Google Scholar
• TopalianSLSznolMMcDermottDFSurvival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabJ Clin Oncol201432101020103024590637
   PubMed Web of Science ®Google Scholar
• WolchokJDKlugerHCallahanMKNivolumab plus ipilimumab in advanced melanomaN Engl J Med2013369212213323724867
   PubMed Web of Science ®Google Scholar
• DouillardJYShepherdFAHirshVMolecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trialJ Clin Oncol201028574475220038723
   PubMed Web of Science ®Google Scholar
• KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med2010363181693170320979469
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• ShawATOuSHBangYJCrizotinib in ROS1-rearranged non-small-cell lung cancerN Engl J Med2014371211963197125264305
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• Al-MoundhriMO’BrienMSouberbielleBEImmunotherapy in lung cancerBr J Cancer19987832822889703271
   PubMed Web of Science ®Google Scholar
• SalgallerMLThe development of immunotherapies for non-small cell lung cancerExpert Opin Biol Ther20022326527811890866
   PubMed Web of Science ®Google Scholar
• LynchTJBondarenkoILuftAIpilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II studyJ Clin Oncol201230172046205422547592
   PubMed Web of Science ®Google Scholar
• BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med2012366262455246522658128
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• YangCYLinMWChangYLWuCTYangPCProgrammed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomesEur J Cancer20145071361136924548766
   PubMed Web of Science ®Google Scholar
• VelchetiVSchalperKACarvajalDEProgrammed death ligand-1 expression in non-small cell lung cancerLab Invest201494110711624217091
   PubMed Web of Science ®Google Scholar
• BolandJMKwonEDHarringtonSMTumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lungClin Lung Cancer201314215716322868219
   PubMed Web of Science ®Google Scholar
• KonishiJYamazakiKAzumaMKinoshitaIDosaka-AkitaHNishimuraMB7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expressionClin Cancer Res200410155094510015297412
   PubMed Web of Science ®Google Scholar
• VelchetiVRimmDLSchalperKASarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1)J Thorac Oncol20138680380523676558
   PubMed Web of Science ®Google Scholar
• ChenYBMuCYHuangJAClinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up studyTumori201298675175523389362
   PubMed Web of Science ®Google Scholar
• MuCYHuangJAChenYChenCZhangXGHigh expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturationMed Oncol201128368268820373055
   PubMed Web of Science ®Google Scholar
• BrahmerJRHornLAntoniaSNivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with non-small cell lung cancer (NSCLC)overall survival and long-term safety in a phase 1 trial. Presented at: IASLC 15th World Conference on Lung CancerSydney, AustraliaOctober 22–302013
   Google Scholar
• GaronEBLeighlNBRizviNASafety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC)Presented at: The American Society of Clinical Oncology Annual MeetingChicago, IL, USAOctober 22–302013
   Google Scholar
• RizviNAGaronEBPatnaikASafety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC)Presented at: The American Society of Clinical Oncology Annual MeetingChicago, IL, USAMay 30–June 3, 2014
   Google Scholar
• FyfeGFisherRIRosenbergSASznolMParkinsonDRLouieACResults of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapyJ Clin Oncol19951336886967884429
   PubMed Web of Science ®Google Scholar
• FisherRIRosenbergSAFyfeGLong-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinomaCancer J Sci Am20006Suppl 1S55S5710685660
   PubMed Web of Science ®Google Scholar
• EscudierBPortaCSchmidingerMRenal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201425Suppl 3iii49iii5625210086
   PubMed Web of Science ®Google Scholar
• CoppinCLeLPorzsoltFWiltTTargeted therapy for advanced renal cell carcinomaCochrane Database Syst Rev20082CD00601718425931
   PubMed Web of Science ®Google Scholar
• ThompsonRHDongHLohseCMPD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinomaClin Cancer Res20071361757176117363529
   PubMed Web of Science ®Google Scholar
• FinkeJHRaymanPAKoJSBradleyJMGendlerSJCohenPAModification of the tumor microenvironment as a novel target of renal cell carcinoma therapeuticsCancer J201319435336423867518
   PubMed Web of Science ®Google Scholar
• KoJSZeaAHRiniBISunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patientsClin Cancer Res20091562148215719276286
   PubMed Web of Science ®Google Scholar
• SfanosKSBrunoTCMarisCHPhenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewingClin Cancer Res200814113254326118519750
   PubMed Web of Science ®Google Scholar
• EbeltKBabarykaGFrankenbergerBProstate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clustersEur J Cancer20094591664167219318244
   PubMed Web of Science ®Google Scholar
• SlovinSFHiganoCSHamidOIpilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II studyAnn Oncol20132471813182123535954
   PubMed Web of Science ®Google Scholar
• Brandwein-GenslerMSmithRVPrognostic indicators in head and neck oncology including the new 7th edition of the AJCC staging systemHead Neck Pathol201041536120237990
   PubMedGoogle Scholar
• MellLKDignamJJSalamaJKPredictors of competing mortality in advanced head and neck cancerJ Clin Oncol2010281152019933920
   PubMed Web of Science ®Google Scholar
• BrocksteinBEVokesEEHead and neck cancer in 2010: maximizing survival and minimizing toxicityNat Rev Clin Oncol201182727421278773
   PubMed Web of Science ®Google Scholar
• SeiwertTBurtnessBWeissJA phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer [abstr 6011]J Clin Oncol201432Suppl5S
   Google Scholar
• DongHStromeSESalomaoDRTumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasionNat Med20028879380012091876
   PubMed Web of Science ®Google Scholar
• GatalicaZSnyderCLYeatsKXiaoNHoltermanDLynchHTProgrammed death 1 (PD-1) lymphocytes and ligand (PD-L1) in colorectal cancer and their relationship to microsatellite instability status [abstr 3625]J Clin Oncol201432Suppl5S
   Google Scholar
• DroeserRAHirtCViehlCTClinical impact of programmed cell death ligand 1 expression in colorectal cancerEur J Cancer20134992233224223478000
   PubMed Web of Science ®Google Scholar
• BrahmerJRDrakeCGWollnerIPhase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesJ Clin Oncol201028193167317520516446
   PubMed Web of Science ®Google Scholar
• LipsonEJSharfmanWHDrakeCGDurable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibodyClin Cancer Res201319246246823169436
   PubMed Web of Science ®Google Scholar
• SznolMChenLAntagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer–responseClin Cancer Res20131919554224048329
   PubMed Web of Science ®Google Scholar
• BergerRRotem-YehudarRSlamaGPhase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignanciesClin Cancer Res200814103044305118483370
   PubMed Web of Science ®Google Scholar
• RobertCLongGVBradyBNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med2015372432033025399552
   PubMed Web of Science ®Google Scholar